Original article
Comparison of methods for assessing synergic antibiotic interactions

https://doi.org/10.1016/S0924-8579(00)00149-7Get rights and content

Abstract

Twenty-five combined microtitre chequerboard/time kill curves were performed on ten isolates from patients with relapsing infection to assess the potential for combination therapy. The isolates were Burkholderia cepacia, Staphylococcus aureus and Klebsiella pneumoniae. No antagonism (FIC index or FBC index >4) was observed with any combination. Synergy by time kill curve (present in 21 combinations) was more often seen at 24 h than 2 or 5 h (P<0.001). On comparing the mean of the FIC and FBC indices, there were significant differences in only four chequerboards (P<0.05). The same checkerboard was repeated on 3 separate days to test reproducibility. There were no significant differences (P>0.05). All combinations showing synergism by FBC index were synergic by FIC index. Synergy by FIC index predicted synergy by FBC index in 67%. All combinations showing synergism by FIC index were synergic by time kill at 24 h but there was poor correlation between synergy at 2 or 5 h and synergy by FIC index or FBC index. In conclusion combining time kill and chequerboard tests gives reproducible results and good correlation between FIC and FBC indices. FIC indices showing synergy were also predictive of synergy in time kill studies. For bactericidal combinations unlikely to be antagonistic, calculation of FIC index may be a good indicator of synergic bactericidal activity.

Introduction

Definitions of synergy and antagonism are a contentious issue. In theory, synergy occurs at a fractional inhibitory concentration (FIC) index or fractional bactericidial concentration (FBC) index of <1, but as the chequerboard method has a ±1 dilution error, convention states that synergy is ≤0.5. However, ‘minor’ synergy, (i.e. up to 1), may be clinically important as argued by Berenbaum [1]. Criteria ranging from >1 to >4 have been used to define antagonism. The >4 rule, is widely accepted as it reduces in the presence of experimental error. Also, lower antagonism criteria may have no clinical significance [2].

The advantage of using a chequerboard technique for studying antibiotic interactions is that it is a commonly used method so data produced can be easily compared with already published studies. The technique is also easy to understand and simple, although time consuming to perform. If time kill studies can be combined with chequerboards, then much more detailed kinetic information can be generated for relatively little extra work.

Several studies have assessed the clinical relevance of in vitro synergy testing. For instance, comparison of in vitro antibiotic combination with clinical outcome in serious infection with Pseudomonas aeruginosa suggested that chequerboards were of little value in predicting clinical outcome [3] but in a study of 30 isolates of P. aeruginosa causing endocarditis, lack of synergy in vitro indicated refractoriness to treatment [4].

In this present study, we describe the in vitro assessment of antibiotic interactions in a series of multi-resistant clinical isolates, from patients with relapsing infection, using the same chequerboard methodology to calculate FIC and FBC indices and time kill curves. In previous studies, we have found this method is both reproducible and gives good correlation between FIC and FBC indices and time kill curves [5], [6].

Section snippets

Bacteria studied

Ten strains were studied: Two Staphylococcus aureus (S, D) isolated from infected hip joints, one Klebsiella pneumoniae isolated from cerebro-spinal fluid of a patient with meningitis and seven Burkholderia cepacia, four isolated from cystic fibrosis patients, (CF26, CF28, CF29 pigmented (CF29p) and CF29 non-pigmented (CF29np)), and the other three from a patient with a chronic cerebellar abscess, (Ps132, Ps 141 sensitive (Ps141s) and Ps141 resistant (Ps141r)). All were recent isolates from

Results

Table 1 details the antibiotic combinations tested against each organism, the MIC of each antibiotic/organism combination, the maximum antibiotic concentrations tested in each chequerboard, the FIC and FBC indices and the concentration of antibiotics demonstrating the most synergic activity. Only 21 of the 25 chequerboards could be used to compare the FIC indices and FBC indices as the rest only produced one set of indices or none. No differences between the means of the FIC and FBC indices

Discussion

There is a widely reported lack of correlation between the chequerboard technique and time-kill studies. Norden et al. [3] postulated that correlation can be increased by performing all the synergy tests on the same day, so reducing the observed variability in results. Combination of all measurements within the chequerboard therefore may reduce this variability as we have found previously [5], [6].

The observed differences between the bacteriostatic and bactericidal results are most likely due

Acknowledgements

We are grateful to Dr M. Allan of Wyeth for support.

References (18)

  • R.P. Hobson et al.

    An outbreak of multiply-resistant Klebsiella pneumoniae in the Grampian region of Scotland

    J. Hosp. Infect.

    (1996)
  • M. Berenbaum

    Minor synergy and antagonism may be clinically important

    J. Antimicrob. Chemother.

    (1987)
  • V.I. Yu et al.

    In vitro synergy testing of triple antibiotic combinations against Staphylococcus epidermidis isolates from patients with endocarditis

    J. Antimicrob. Chemother.

    (1984)
  • C. Norden

    Comparison of techniques for measurements of an in vitro antibiotic synergism

    J. Infect. Dis.

    (1979)
  • M.P. Reyes et al.

    Synergy between carbenicillin and aminoglycoside (gentamicin or tobramycin) against Pseudomonas aeruginosa isolated from patients with endocarditis and sensitivity of isolates to normal human serum

    J. Infect. Dis.

    (1979)
  • I.M. Gould et al.

    Interaction of imipenem with erythromycin and tetracycline assessed by microdilution checkerboard techniques

    Antimicrob. Agents Chemother.

    (1991)
  • I.M. Gould et al.

    In vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin

    J. Antimicrob. Chemother.

    (1997)
  • S. Hodge et al.
  • Lorian V, editor. Antibiotics in Laboratory Medicine. London: Williams and Wilkins, 1986 [chapter 5] pp....
There are more references available in the full text version of this article.

Cited by (107)

  • Prevention, inhibition, and degradation effects of melittin alone and in combination with vancomycin and rifampin against strong biofilm producer strains of methicillin-resistant Staphylococcus epidermidis

    2022, Biomedicine and Pharmacotherapy
    Citation Excerpt :

    Afterward, FBECi for the two combined antibacterial agents was calculated as follows: FBECi = (MBEC drug A in combination/ MBEC drug A alone) + (MBEC drug B in combination/ MBEC drug B alone). FBEC indices are pointed to the kind of drug interaction if the following data are established: Synergy, values n ≤ 0.5; Partial synergy, values 0.5 < n < 1; Additive effect, for a value n = 1; Indifferent effect, for values 1 < n < 4; Antagonistic effect, for a value 4 ≤ n [23,24,51]. Biofilm forming S. epidermidis isolates include strong biofilm-forming MRSE 1, strong biofilm-forming MRSE 4, moderate biofilm-forming MRSE 5, moderate biofilm-forming MSSE 1, as well as strong biofilm-forming S. epidermidis ATCC 35984 were used for evaluation of biofilm-associated expression genes (icaA, aap, and psmβ) by real-time PCR.

View all citing articles on Scopus
View full text